There are 3 listed Animal Health stocks in India: Viyash Scientific (₹10,314 crore), Hester Biosciences (₹1,982 crore) and NGL Fine Chem (₹1,698 crore), at prices of 20 November 2026. 0 of the 3 companies we track are beating the Nifty 500 on share price over recent months.
Animal Health: Viyash Scientific Ltd owns the largest revenue base; NGL Fine Chem Ltd has the fastest current growth.
The main question: the biggest companies are not always the ones changing the most.
Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.
How big is the Animal Health sector?
There are 3 listed Animal Health companies on this page, worth ₹14,000 cr together at prices of 20 November 2026. Viyash Scientific alone is ₹10,300 cr, about 74% of the total.
Market values at prices of 20 November 2026.
What did Animal Health managements say about July to September 2026?
3 of 3 Pharma - Animal companies held a results call for July to September 2026. Viyash Scientific guided: FY27 revenue growth more than 20%, up from mid-teens initial view shared on call.
Viyash Scientific call 14 November 2026
“With these products, Vishal, if you achieve a first day-one launch, you can secure 50-60% market share even after someone else enters. That is where we see the value in this product.”Dr Hari Babu
Guided: FY27 revenue growth more than 20%, up from mid-teens initial view shared on call.
NGL Fine Chem call 12 November 2026
“Our focus now is on converting the investment in capacity and working capital into sales, operating cash flow, and improved results.”Rahul Nachane
Guided: Phase II utilization 30-40% over next 2-3 quarters with room for both regulated and existing demand for next 3 years.
Hester Biosciences call 5 November 2026
“Overall, you can take it as a basket. We foresee that poultry will continue at worst at this base; it cannot go down, and it can only improve. We will also add ruminant vaccines.”Rajiv Gandhi
Guided: Sustain poultry growth through introductions, penetration and geo expansion for remainder FY27.
From the results calls for July to September 2026.
Is money moving into Animal Health stocks? Who is adding capacity?
Big funds, foreign and Indian, cut their stake by 0.8 points over the last two quarters. Founders and promoters kept theirs about the same.
- Spending on new plants and equipment was ₹173 crore in the last 12 months, 68% less than a year before.
- Projects still being built shrank 37% in a year.
Big funds = foreign and Indian institutions, change in their share of ownership across 3 Pharma - Animal companies, in percentage points.
Ownership and spending as of 10 October 2026.
What to watch next in Animal Health stocks?
The next things that show whether the Pharma - Animal story is on course. First: Viyash's next reported quarter confirms ingredient-order recovery and Vizag commercialization without another procurement pause.
- Hester's next reported quarter shows the promised government vaccine sales rather than another delay.
- Viyash's expected reduction in employee-option and goodwill charges improves profit conversion, with operating gains separated from accounting effects.
- Hester demonstrates positive operating cash flow and better receivables collection.
- Viyash confirms BioForLife closing and the subsequent registration work.
What would change the story
A reported industry quarter showing lower revenue and lower operating margin together with lower profit than a year earlier would break the earnings-supported breakout call.
From our industry review of 10 October 2026.
Which are the biggest Animal Health stocks in India?
The largest Animal Health stocks in India by market value are Viyash Scientific (₹10,314 crore), Hester Biosciences (₹1,982 crore) and NGL Fine Chem (₹1,698 crore), at prices of 20 Nov 2026.
- Viyash Scientific: ₹233.36 | market value ₹10,314 crore | P/E 40.2
- Hester Biosciences: ₹2,329.90 | market value ₹1,982 crore | P/E 13.9
- NGL Fine Chem: ₹2,747.60 | market value ₹1,698 crore | P/E 24.0
Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 20 Nov 2026; the score list below uses the weekly figures.
Is there a Nifty Animal Health index, and what is in it?
All 3 listed Indian Pharma - Animal companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Pharma - Animal index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. One large company cannot set the reading.
- Viyash Scientific Ltd₹10,300 cr
- Hester Biosciences Ltd₹1,980 cr
- NGL Fine Chem Ltd₹1,700 cr
How many Animal Health companies are listed in India?
3 Animal Health companies in the Pharma - Animal industry group have a page on Sector Alpha, and all 3 are listed below, largest first. The largest is Viyash Scientific (₹10,314 crore) and the smallest with a market value is NGL Fine Chem.
| Company | Market value |
|---|---|
| 1. Viyash Scientific Ltd VIYASH | ₹10,314 crore |
| 2. Hester Biosciences Ltd HESTERBIO | ₹1,982 crore |
| 3. NGL Fine Chem Ltd NGLFINE | ₹1,698 crore |
How have Animal Health stocks moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 38% ahead of NIFTY 500. Earnings across its companies grew 131% on average over the last four reported quarters.
Price and the fundamentals both up. 0 of 3 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).
Not ahead of NIFTY 500 on the three-month view this week; 3 of the 3 companies in the industry index above their 200-day average (1 more than four weeks earlier); 0 of those 3 pass the momentum test (no change from four weeks earlier); earnings rising at 2 of the 3 that report earnings.
Not ahead of NIFTY 500, not building participation, not giving any back. Earnings confirming, 2 of 3 members have higher trailing twelve-month earnings than a year ago. The largest member is more than half the sector's market value and is moving the other way.
1Y
Pharma - Animal against NIFTY 500
Both lines start at 200 in the first week shown
- Animal Health 313
- NIFTY 500 200
| Week ending | Animal Health | NIFTY 500 |
|---|---|---|
| 21 Nov 2025 | 200 | 200 |
| 28 Nov 2025 | 195 | 201 |
| 5 Dec 2025 | 186 | 200 |
| 12 Dec 2025 | 188 | 199 |
| 19 Dec 2025 | 186 | 199 |
| 26 Dec 2025 | 189 | 200 |
| 2 Jan 2026 | 192 | 203 |
| 9 Jan 2026 | 188 | 197 |
| 16 Jan 2026 | 187 | 197 |
| 23 Jan 2026 | 188 | 191 |
| 30 Jan 2026 | 200 | 194 |
| 6 Feb 2026 | 218 | 197 |
| 13 Feb 2026 | 229 | 196 |
| 20 Feb 2026 | 232 | 197 |
| 27 Feb 2026 | 228 | 195 |
| 6 Mar 2026 | 224 | 189 |
| 13 Mar 2026 | 210 | 180 |
| 20 Mar 2026 | 208 | 179 |
| 27 Mar 2026 | 202 | 177 |
| 3 Apr 2026 | 209 | 176 |
| 10 Apr 2026 | 223 | 188 |
| 17 Apr 2026 | 221 | 192 |
| 24 Apr 2026 | 221 | 190 |
| 1 May 2026 | 227 | 191 |
| 8 May 2026 | 237 | 194 |
| 15 May 2026 | 248 | 189 |
| 22 May 2026 | 272 | 190 |
| 29 May 2026 | 286 | 190 |
| 5 Jun 2026 | 280 | 189 |
| 12 Jun 2026 | 288 | 190 |
| 19 Jun 2026 | 296 | 195 |
| 26 Jun 2026 | 307 | 194 |
| 3 Jul 2026 | 322 | 196 |
| 10 Jul 2026 | 312 | 196 |
| 17 Jul 2026 | 322 | 196 |
| 24 Jul 2026 | 314 | 193 |
| 31 Jul 2026 | 321 | 197 |
| 7 Aug 2026 | 334 | 199 |
| 14 Aug 2026 | 327 | 198 |
| 21 Aug 2026 | 318 | 198 |
| 28 Aug 2026 | 307 | 198 |
| 4 Sep 2026 | 314 | 195 |
| 11 Sep 2026 | 296 | 192 |
| 18 Sep 2026 | 294 | 192 |
| 25 Sep 2026 | 296 | 190 |
| 2 Oct 2026 | 289 | 184 |
| 9 Oct 2026 | 287 | 184 |
| 16 Oct 2026 | 287 | 187 |
| 23 Oct 2026 | 265 | 180 |
| 30 Oct 2026 | 278 | 184 |
| 6 Nov 2026 | 301 | 197 |
| 13 Nov 2026 | 313 | 200 |
3Y
Pharma - Animal against NIFTY 500
Both lines start at 200 in the first week shown, every 2nd week shown
- Animal Health 406
- NIFTY 500 269
| Week ending | Animal Health | NIFTY 500 |
|---|---|---|
| 24 Nov 2023 | 200 | 200 |
| 1 Dec 2023 | 199 | 205 |
| 15 Dec 2023 | 196 | 217 |
| 29 Dec 2023 | 200 | 220 |
| 12 Jan 2024 | 212 | 224 |
| 26 Jan 2024 | 204 | 220 |
| 9 Feb 2024 | 200 | 226 |
| 23 Feb 2024 | 214 | 230 |
| 8 Mar 2024 | 201 | 232 |
| 22 Mar 2024 | 199 | 227 |
| 5 Apr 2024 | 219 | 235 |
| 19 Apr 2024 | 223 | 231 |
| 3 May 2024 | 226 | 238 |
| 17 May 2024 | 221 | 239 |
| 31 May 2024 | 211 | 239 |
| 14 Jun 2024 | 233 | 252 |
| 28 Jun 2024 | 249 | 256 |
| 12 Jul 2024 | 282 | 262 |
| 26 Jul 2024 | 308 | 264 |
| 9 Aug 2024 | 281 | 260 |
| 23 Aug 2024 | 283 | 265 |
| 6 Sep 2024 | 284 | 266 |
| 20 Sep 2024 | 279 | 274 |
| 4 Oct 2024 | 286 | 267 |
| 18 Oct 2024 | 288 | 266 |
| 1 Nov 2024 | 283 | 259 |
| 15 Nov 2024 | 279 | 249 |
| 29 Nov 2024 | 289 | 257 |
| 13 Dec 2024 | 281 | 265 |
| 27 Dec 2024 | 268 | 254 |
| 10 Jan 2025 | 261 | 247 |
| 24 Jan 2025 | 255 | 242 |
| 7 Feb 2025 | 244 | 245 |
| 21 Feb 2025 | 198 | 235 |
| 7 Mar 2025 | 192 | 232 |
| 21 Mar 2025 | 186 | 241 |
| 4 Apr 2025 | 197 | 236 |
| 18 Apr 2025 | 201 | 246 |
| 2 May 2025 | 200 | 249 |
| 16 May 2025 | 232 | 259 |
| 30 May 2025 | 228 | 258 |
| 13 Jun 2025 | 227 | 260 |
| 27 Jun 2025 | 224 | 268 |
| 11 Jul 2025 | 237 | 264 |
| 25 Jul 2025 | 231 | 261 |
| 8 Aug 2025 | 231 | 254 |
| 22 Aug 2025 | 251 | 261 |
| 5 Sep 2025 | 265 | 259 |
| 19 Sep 2025 | 263 | 266 |
| 3 Oct 2025 | 257 | 261 |
| 17 Oct 2025 | 256 | 268 |
| 31 Oct 2025 | 255 | 269 |
| 14 Nov 2025 | 258 | 270 |
| 28 Nov 2025 | 252 | 271 |
| 12 Dec 2025 | 244 | 269 |
| 26 Dec 2025 | 244 | 270 |
| 9 Jan 2026 | 243 | 266 |
| 23 Jan 2026 | 243 | 257 |
| 6 Feb 2026 | 282 | 266 |
| 20 Feb 2026 | 300 | 265 |
| 6 Mar 2026 | 290 | 255 |
| 20 Mar 2026 | 269 | 242 |
| 3 Apr 2026 | 270 | 237 |
| 17 Apr 2026 | 287 | 259 |
| 1 May 2026 | 293 | 257 |
| 15 May 2026 | 322 | 255 |
| 29 May 2026 | 370 | 257 |
| 12 Jun 2026 | 373 | 256 |
| 26 Jun 2026 | 397 | 262 |
| 10 Jul 2026 | 404 | 265 |
| 24 Jul 2026 | 407 | 260 |
| 7 Aug 2026 | 433 | 269 |
| 21 Aug 2026 | 411 | 267 |
| 4 Sep 2026 | 407 | 264 |
| 18 Sep 2026 | 380 | 259 |
| 2 Oct 2026 | 374 | 248 |
| 16 Oct 2026 | 372 | 252 |
| 30 Oct 2026 | 360 | 248 |
| 13 Nov 2026 | 406 | 269 |
5Y
Pharma - Animal against NIFTY 500
Both lines start at 200 in the first week shown, every 4th week shown
- Animal Health 323
- NIFTY 500 323
| Week ending | Animal Health | NIFTY 500 |
|---|---|---|
| 26 Nov 2021 | 200 | 200 |
| 17 Dec 2021 | 205 | 200 |
| 14 Jan 2022 | 222 | 214 |
| 11 Feb 2022 | 189 | 203 |
| 11 Mar 2022 | 175 | 194 |
| 8 Apr 2022 | 206 | 209 |
| 6 May 2022 | 175 | 192 |
| 3 Jun 2022 | 160 | 191 |
| 1 Jul 2022 | 145 | 182 |
| 29 Jul 2022 | 164 | 199 |
| 26 Aug 2022 | 153 | 206 |
| 23 Sep 2022 | 143 | 205 |
| 21 Oct 2022 | 137 | 205 |
| 18 Nov 2022 | 144 | 211 |
| 16 Dec 2022 | 137 | 213 |
| 13 Jan 2023 | 129 | 209 |
| 10 Feb 2023 | 124 | 204 |
| 10 Mar 2023 | 121 | 200 |
| 7 Apr 2023 | 121 | 201 |
| 5 May 2023 | 129 | 208 |
| 2 Jun 2023 | 120 | 215 |
| 30 Jun 2023 | 146 | 223 |
| 28 Jul 2023 | 145 | 230 |
| 25 Aug 2023 | 151 | 229 |
| 22 Sep 2023 | 146 | 235 |
| 20 Oct 2023 | 152 | 234 |
| 17 Nov 2023 | 147 | 239 |
| 15 Dec 2023 | 156 | 260 |
| 12 Jan 2024 | 169 | 269 |
| 9 Feb 2024 | 159 | 271 |
| 8 Mar 2024 | 160 | 278 |
| 5 Apr 2024 | 174 | 282 |
| 3 May 2024 | 180 | 285 |
| 31 May 2024 | 168 | 287 |
| 28 Jun 2024 | 198 | 307 |
| 26 Jul 2024 | 245 | 317 |
| 23 Aug 2024 | 225 | 318 |
| 20 Sep 2024 | 222 | 329 |
| 18 Oct 2024 | 229 | 319 |
| 15 Nov 2024 | 222 | 299 |
| 13 Dec 2024 | 223 | 318 |
| 10 Jan 2025 | 207 | 296 |
| 7 Feb 2025 | 194 | 294 |
| 7 Mar 2025 | 153 | 278 |
| 4 Apr 2025 | 157 | 283 |
| 2 May 2025 | 159 | 299 |
| 30 May 2025 | 181 | 310 |
| 27 Jun 2025 | 178 | 321 |
| 25 Jul 2025 | 184 | 313 |
| 22 Aug 2025 | 199 | 313 |
| 19 Sep 2025 | 209 | 319 |
| 17 Oct 2025 | 204 | 321 |
| 14 Nov 2025 | 206 | 324 |
| 12 Dec 2025 | 194 | 323 |
| 9 Jan 2026 | 193 | 319 |
| 6 Feb 2026 | 225 | 319 |
| 6 Mar 2026 | 231 | 306 |
| 3 Apr 2026 | 215 | 285 |
| 1 May 2026 | 233 | 308 |
| 29 May 2026 | 294 | 308 |
| 26 Jun 2026 | 316 | 314 |
| 24 Jul 2026 | 324 | 312 |
| 21 Aug 2026 | 327 | 320 |
| 18 Sep 2026 | 303 | 311 |
| 16 Oct 2026 | 296 | 303 |
| 13 Nov 2026 | 323 | 323 |
Earnings, each company rebased to 100, the sector takes the median
Latest quarter July to September 2026: 326.2, from 2 companies
| Quarter | Median earnings index |
|---|---|
| Jul 2023 | 100.0 (2 companies) |
| Oct 2023 | 95.4 (2 companies) |
| Jan 2024 | 101.3 (2 companies) |
| Apr 2024 | 103.2 (2 companies) |
| Jul 2024 | 108.3 (2 companies) |
| Oct 2024 | 104.3 (2 companies) |
| Jan 2025 | 78.1 (2 companies) |
| Apr 2025 | 93.4 (2 companies) |
| Jul 2025 | 102.4 (2 companies) |
| Oct 2025 | 123.5 (2 companies) |
| Jan 2026 | 168.4 (2 companies) |
| Apr 2026 | 305.6 (2 companies) |
| Jul 2026 | 326.2 (2 companies) |
Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 3 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.
Are Animal Health stocks outperforming NIFTY 500?
Pharma - Animal has done better than the NIFTY 500 by 34.7% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 6.3%. NGL Fine Chem Ltd is the strongest against the sector itself at +12.3%.
What is the bottom line on Animal Health stocks?
Pharma - Animal has done better than the NIFTY 500 by 34.7% over 52 weeks, but is 6.3% behind over the last 13 weeks. 0 of 3 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 1 of the 2 with a long enough price history is ahead of the industry itself.
How does each Animal Health stock score?
A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.
NGL Fine Chem Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 87% evidence confidence.
- 1NGL Fine Chem LtdNGLFINE · quiet · favourable · 87% evidence77.6out of 100
How the score adds up
Growth & earnings 35.0/35 · Revenue 40.9% · PAT 100% · OPM change 4 pp · 100% evidenceCapital efficiency 18.4/25 · ROCE 18.6% (year to Mar 2026) · OPM 17.6% · 100% evidenceValuation 10.2/20 · P/E 26.6× · PEG — · 35% evidenceRelative strength 14.0/20 · RS sector 12.3% · RS bench 20.7% · 1Y 105.8% · 100% evidence · 0 of 12 weeks aheadExact sum: 35 + 18.4 + 10.2 + 14 = 77.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Hester Biosciences LtdHESTERBIO · quiet · favourable · 64% evidence74.4out of 100
How the score adds up
Growth & earnings 33.2/35 · Revenue 17.3% · PAT 100% · OPM change 16 pp · 95% evidenceCapital efficiency 16.5/25 · ROCE 15.2% (year to Mar 2026) · OPM 33.7% · 76% evidenceValuation 12.2/20 · P/E 13.9× · PEG — · 35% evidenceRelative strength 12.5/20 · RS sector — · RS bench 19.3% · 1Y 39.4% · 25% evidence · 4 of 12 weeks aheadExact sum: 33.2 + 16.5 + 12.2 + 12.5 = 74.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Viyash Scientific LtdVIYASH · quiet · mixed, leaning good · 79% evidence62.7out of 100
How the score adds up
Growth & earnings 26.0/35 · Revenue 31.7% · PAT 72.2% · OPM change −3 pp · 95% evidenceCapital efficiency 12.3/25 · ROCE 13.4% (year to Mar 2026) · OPM 16.7% · 76% evidenceValuation 11.5/20 · P/E 44× · PEG — · 35% evidenceRelative strength 12.9/20 · RS sector −2.8% · RS bench 7.1% · 1Y −2.2% · 100% evidence · 0 of 12 weeks aheadExact sum: 26 + 12.3 + 11.5 + 12.9 = 62.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
How this score is built, and what the marks mean
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
How have Animal Health share prices moved?
NGL Fine Chem Ltd has the strongest one-year price move in Pharma - Animal at +105.8%. It also leads on relative strength against the NIFTY, at +20.7%. 3 of 3 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.
Price and relative strength
Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
RS vs sector: The same measure taken against Pharma - Animal itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
Biggest one-year moves
- 1NGL Fine Chem LtdNGLFINE · ₹1,700 cr+105.8%1 year
- 2Hester Biosciences LtdHESTERBIO · ₹1,980 cr+39.4%1 year
- 3Viyash Scientific LtdVIYASH · ₹10,300 cr−2.2%1 year
Strongest against NIFTY 500
- 1NGL Fine Chem LtdNGLFINE · ₹1,700 cr+20.7%vs NIFTY 500
- 2Hester Biosciences LtdHESTERBIO · ₹1,980 cr+19.3%vs NIFTY 500
- 3Viyash Scientific LtdVIYASH · ₹10,300 cr+7.1%vs NIFTY 500
Strongest against the sector itself
- 1NGL Fine Chem LtdNGLFINE · ₹1,700 cr+12.3%vs sector
- 2Viyash Scientific LtdVIYASH · ₹10,300 cr−2.8%vs sector
Why are Animal Health stocks moving?
An established breakout and earnings recovery, with concentrated gains, high margins and weakening recent performance against the index. In the week of 5 October 2026, 100% of 3 Pharma - Animal companies were beating the Nifty 500, against 100% on 25 May 2026.
Pharma - Animal: share of companies beating the Nifty 500, and above their 200-day average, to 5 October 2026, last sector review
- Beating the Nifty 500 100%
- Above the 200-day average 66.7%
| Week | Beating the Nifty 500 | Above the 200-day average |
|---|---|---|
| 25 May 2026 | 100% | 100% |
| 1 Jun 2026 | 100% | 100% |
| 8 Jun 2026 | 100% | 100% |
| 15 Jun 2026 | 100% | 100% |
| 22 Jun 2026 | 100% | 100% |
| 29 Jun 2026 | 100% | 100% |
| 6 Jul 2026 | 100% | 100% |
| 13 Jul 2026 | 100% | 100% |
| 20 Jul 2026 | 100% | 100% |
| 27 Jul 2026 | 100% | 100% |
| 3 Aug 2026 | 100% | 100% |
| 10 Aug 2026 | 100% | 100% |
| 17 Aug 2026 | 100% | 100% |
| 24 Aug 2026 | 100% | 100% |
| 31 Aug 2026 | 100% | 100% |
| 7 Sep 2026 | 100% | 100% |
| 14 Sep 2026 | 100% | 100% |
| 21 Sep 2026 | 100% | 100% |
| 28 Sep 2026 | 100% | 66.7% |
| 5 Oct 2026 | 100% | 66.7% |
From our industry review of 10 October 2026.
What is changing for Animal Health companies?
Both readable companies describe better efficiency, product mix and capacity use, but their recovery is uneven. Viyash's improvement includes human medicines, while Hester's government vaccine orders remain delayed.
| What is changing | Which companies | Lasting? |
|---|---|---|
| Costs spread over more sales | Both companies with readable calls: Viyash and Hester; NGL Fine Chem is unverified. | too early to call |
| Higher-value products and a better mix | Hester reports a favorable mix; Viyash describes selected launches and India-sourced products improving its US human-medicine business. | too early to call |
| New products | Both readable companies have launch evidence; further launches remain conditional. | too early to call |
From our industry review of 10 October 2026.
Which Animal Health companies have the most revenue, and which grow fastest?
Viyash Scientific Ltd has the highest Revenue among the 3 Pharma - Animal companies compared here, at ₹3,712 crore. NGL Fine Chem Ltd is next at ₹575 crore. NGL Fine Chem Ltd has the highest Revenue growth at 40.9%, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Viyash Scientific Ltd is the largest at ₹3,712 crore, 545.6% ahead of NGL Fine Chem Ltd. NGL Fine Chem Ltd's growth is 40.9% from a ₹575 crore base, with 20 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.
What this means: Viyash Scientific Ltd is the size to compare against; NGL Fine Chem Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.
This conclusion weakens if: Viyash Scientific Ltd's growth falls below NGL Fine Chem Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenue · company comparison
Revenue · largest
- 1Viyash Scientific LtdVIYASH₹3,710 cr
- 2NGL Fine Chem LtdNGLFINE₹575 cr
- 3Hester Biosciences LtdHESTERBIO₹352 cr
Revenue growth · fastest growers
- 1NGL Fine Chem LtdNGLFINE41%
- 2Viyash Scientific LtdVIYASH32%
- 3Hester Biosciences LtdHESTERBIO17%
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Viyash Scientific Ltd VIYASH | ₹988 cr | 16% | Sep 2026 |
| NGL Fine Chem Ltd NGLFINE | ₹159 cr | 33% | Sep 2026 |
| Hester Biosciences Ltd HESTERBIO | ₹98 cr | 38% | Sep 2026 |
Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.
What to watch
Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.
Which Animal Health companies keep the most from each ₹100 of sales?
Hester Biosciences Ltd has the highest OPM among the 3 Pharma - Animal companies compared here, at 33.7%. NGL Fine Chem Ltd is next at 17.6%. The same company also has the highest Margin change, at +16 percentage points. 3 of 3 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: Hester Biosciences Ltd leads both opm at 33.7% and margin change at +16 percentage points.
What this means: Hester Biosciences Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
Operating margin · company comparison
OPM, by reported quarter
- Hester Biosciences 33%
- NGL Fine Chem 18%
- Viyash Scientific 17%
| Quarter | Hester Biosciences | NGL Fine Chem | Viyash Scientific |
|---|---|---|---|
| Dec 2021 | 27% | 15% | 10% |
| Mar 2022 | 18% | 13% | 8.7% |
| Jun 2022 | 15% | 3.3% | 0.6% |
| Sep 2022 | 17% | 14% | 0.9% |
| Dec 2022 | 25% | 14% | 3.0% |
| Mar 2023 | 17% | 19% | −0.9% |
| Jun 2023 | 16% | 14% | −2.5% |
| Sep 2023 | 19% | 17% | 4.4% |
| Dec 2023 | 15% | 16% | 7.0% |
| Mar 2024 | 20% | 16% | 9.0% |
| Jun 2024 | 21% | 10% | 11% |
| Sep 2024 | 23% | 12% | 11% |
| Dec 2024 | 8.0% | 6.0% | 13% |
| Mar 2025 | 23% | 7.0% | 12% |
| Jun 2025 | 27% | 11% | 15% |
| Sep 2025 | 17% | 14% | 20% |
| Dec 2025 | 23% | 18% | 20% |
| Mar 2026 | 34% | 14% | 20% |
| Jun 2026 | 29% | 17% | 19% |
| Sep 2026 | 33% | 18% | 17% |
Margin change, by reported quarter
- Hester Biosciences +16.0 pp
- NGL Fine Chem +4.0 pp
- Viyash Scientific −3.0 pp
| Quarter | Hester Biosciences | NGL Fine Chem | Viyash Scientific |
|---|---|---|---|
| Dec 2021 | −10.2 pp | −15.4 pp | −8.1 pp |
| Mar 2022 | −12.5 pp | −16.4 pp | −3.3 pp |
| Jun 2022 | −13.7 pp | −27.8 pp | −5.7 pp |
| Sep 2022 | −10.6 pp | −8.4 pp | −4.8 pp |
| Dec 2022 | −2.0 pp | −1.4 pp | −7.1 pp |
| Mar 2023 | −1.3 pp | +6.4 pp | −9.6 pp |
| Jun 2023 | +1.4 pp | +10.7 pp | −3.1 pp |
| Sep 2023 | +1.6 pp | +3.5 pp | +3.6 pp |
| Dec 2023 | −10.0 pp | +2.0 pp | +4.0 pp |
| Mar 2024 | +3.0 pp | −3.0 pp | +9.9 pp |
| Jun 2024 | +5.0 pp | −4.0 pp | +13.5 pp |
| Sep 2024 | +4.0 pp | −5.0 pp | +6.6 pp |
| Dec 2024 | −7.0 pp | −10.0 pp | +6.0 pp |
| Mar 2025 | +3.0 pp | −9.0 pp | +3.0 pp |
| Jun 2025 | +6.0 pp | +1.0 pp | +4.0 pp |
| Sep 2025 | −6.0 pp | +2.0 pp | +9.0 pp |
| Dec 2025 | +15.0 pp | +12.0 pp | +7.0 pp |
| Mar 2026 | +11.0 pp | +7.0 pp | +8.0 pp |
| Jun 2026 | +2.0 pp | +6.0 pp | +4.0 pp |
| Sep 2026 | +16.0 pp | +4.0 pp | −3.0 pp |
3 of 3 companies report OPM, 3 of 3 margin change.
OPM · highest
- 1Hester Biosciences LtdHESTERBIO34%
- 2NGL Fine Chem LtdNGLFINE18%
- 3Viyash Scientific LtdVIYASH17%
Margin change · fastest expanders
- 1Hester Biosciences LtdHESTERBIO+16.0 pp
- 2NGL Fine Chem LtdNGLFINE+4.0 pp
- 3Viyash Scientific LtdVIYASH−3.0 pp
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Hester Biosciences Ltd HESTERBIO | 33% | +16.0 pp | Sep 2026 |
| NGL Fine Chem Ltd NGLFINE | 18% | +4.0 pp | Sep 2026 |
| Viyash Scientific Ltd VIYASH | 17% | −3.0 pp | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current margin change rather than reversing it.
Which Animal Health companies earn the most profit?
Viyash Scientific Ltd has the highest Net profit among the 3 Pharma - Animal companies compared here, at ₹279 crore. Hester Biosciences Ltd is next at ₹144 crore. Hester Biosciences Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Viyash Scientific Ltd earns the most, ₹279 crore of profit over the last 12 months, 93.8% above Hester Biosciences Ltd. Hester Biosciences Ltd shows at least 100% on the scoring scale (227.3% in full) growth from a profit base of ₹144 crore. A fast rate from a small base matters less than a large profit that keeps coming.
What this means: Viyash Scientific Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profit · company comparison
Net profit · largest
- 1Viyash Scientific LtdVIYASH₹279 cr
- 2Hester Biosciences LtdHESTERBIO₹144 cr
- 3NGL Fine Chem LtdNGLFINE₹63 cr
Profit growth · fastest growers
- 1Hester Biosciences LtdHESTERBIO100%
- 2NGL Fine Chem LtdNGLFINE100%
- 3Viyash Scientific LtdVIYASH72%
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Viyash Scientific Ltd VIYASH | ₹85 cr | 16% | Sep 2026 |
| Hester Biosciences Ltd HESTERBIO | ₹21 cr | 50% | Sep 2026 |
| NGL Fine Chem Ltd NGLFINE | ₹16 cr | 60% | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.
Which Animal Health companies earn the best return on capital?
NGL Fine Chem Ltd has the highest ROCE among the 3 Pharma - Animal companies compared here, at 18.6%. Hester Biosciences Ltd is next at 15.2%. The same company also has the highest ROCE change, at +10.2 percentage points. 3 of 3 companies report a comparable reading, the latest through Sep 2026.
What the numbers say: NGL Fine Chem Ltd leads ROCE at 18.6%, 3.4 percentage points above Hester Biosciences Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.
What this means: NGL Fine Chem Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
Return on capital · company comparison
Withheld from this chart: Viyash Scientific Ltd (VIYASH): its two data sources disagree by up to 362% on reported income across 15 comparable periods, so its derived ratios are withheld; Hester Biosciences Ltd (HESTERBIO): its two data sources disagree by up to 16% on reported income across 15 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn, the gap is a decision, not missing data.
ROCE · highest
- 1NGL Fine Chem LtdNGLFINE19%
ROCE change · fastest improvers
- 1NGL Fine Chem LtdNGLFINE+10.2 pp
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| NGL Fine Chem Ltd NGLFINE | 18% | +10.2 pp | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current roce change rather than reversing it.
How are Animal Health stocks valued against growth and quality?
No company in this Pharma - Animal comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, Hester Biosciences Ltd is lowest at 13.9× at the latest share price, across 3 of 3 companies with a usable reading.
What the numbers say: There is not enough comparable evidence to name a reliable peg leader.
What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
Valuation · company comparison
P/E, by reported quarter
- Viyash Scientific 48.7×
- Hester Biosciences 35.0×
- NGL Fine Chem 31.4×
| Quarter | Viyash Scientific | Hester Biosciences | NGL Fine Chem |
|---|---|---|---|
| Dec 2021 | 56.2× | 45.7× | 25.9× |
| Mar 2022 | 63.5× | 49.2× | 20.6× |
| Jun 2022 | 58.4× | 43.7× | 20.3× |
| Sep 2022 | 90.8× | 55.6× | 29.2× |
| Dec 2022 | 210.9× | 56.2× | 43.1× |
| Mar 2023 | 182.1× | 43.4× | 40.0× |
| Jun 2023 | — | 54.7× | 56.6× |
| Sep 2023 | — | 49.6× | 41.8× |
| Dec 2023 | — | 48.3× | 39.6× |
| Mar 2024 | — | 64.2× | 33.7× |
| Jun 2024 | — | 108.1× | 35.2× |
| Sep 2024 | 244.3× | 109.2× | 30.3× |
| Dec 2024 | 229.2× | 86.9× | 27.0× |
| Mar 2025 | 60.1× | 34.3× | 21.4× |
| Jun 2025 | 168.7× | 57.1× | 30.7× |
| Sep 2025 | 53.3× | 43.5× | 41.1× |
| Dec 2025 | 65.3× | 30.8× | 39.5× |
| Mar 2026 | 56.4× | 27.4× | 37.3× |
| Jun 2026 | 58.9× | 35.4× | 38.4× |
| Sep 2026 | 48.7× | 35.0× | 31.4× |
0 of 3 companies report PEG, 3 of 3 P/E.
PEG · lowest PEG
Not enough comparable data.
P/E · lowest P/E
- 1Hester Biosciences LtdHESTERBIO13.9×
- 2NGL Fine Chem LtdNGLFINE26.6×
- 3Viyash Scientific LtdVIYASH44.0×
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| NGL Fine Chem Ltd NGLFINE | 0.6 | 31.4× | Sep 2026 |
| Viyash Scientific Ltd VIYASH | — | 48.7× | Sep 2026 |
| Hester Biosciences Ltd HESTERBIO | — | 35.0× | Sep 2026 |
What to watch
Watch whether the next two comparable periods confirm the current p/e rather than reversing it.
Which stock lists do Animal Health companies appear on?
Pharma - Animal companies show up on one of our India lists. The most are on the pharma stocks list (3 companies).
What can make this comparison misleading?
This Pharma - Animal comparison names 6 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 2 have second-source figures left out because the two sources disagree. 1 of the 5 ranked sections has fewer than three usable current readings.
Keep these limits visible
- A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
- A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
- The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 2 companies are missing from the second-source figures on purpose: the two sources disagree, so nothing from the second is drawn. Those rows have less evidence; that does not make the business weaker.
- Thin comparisons: Valuation have fewer than three usable current readings.
How was this comparison built?
This comparison is built from the reported filings of 3 Pharma - Animal companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.
2 of 3 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Viyash Scientific Ltd (VIYASH): its two data sources disagree by up to 362% on reported income across 15 comparable periods, so its derived ratios are withheld; Hester Biosciences Ltd (HESTERBIO): its two data sources disagree by up to 16% on reported income across 15 comparable periods, so its derived ratios are withheld.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
What else do people ask about Animal Health stocks?
These 21 answers restate the Pharma - Animal comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.
Is the Animal Health sector outperforming NIFTY 500?
Pharma - Animal has done better than the NIFTY 500 by 34.7% over 52 weeks, but is 6.3% behind over the last 13 weeks.
0 of 3 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 1 of the 2 with a long enough price history is ahead of the industry itself.
Which Animal Health company is largest by revenue?
Viyash Scientific Ltd leads with revenue of ₹3,712 crore, based on 3 of 3 comparable companies through Sep 2026.
Which Animal Health company is growing fastest?
NGL Fine Chem Ltd has the fastest current revenue growth at 40.9%, across 3 of 3 comparable companies.
Which Animal Health company has the strongest 4-Factor Sector Score?
NGL Fine Chem Ltd ranks first at 77.6 out of 100, with 87% of the evidence available. The score ranks published data; it is not a recommendation.
How much history does this Animal Health comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.
Is there a Nifty Animal Health index?
The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.
Whether or not an official Nifty index covers Pharma - Animal, this page builds its own equal-weight basket of 3 listed Pharma - Animal companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.
Which are the best Animal Health stocks in India?
Ranked by this page's four-factor score, NGL Fine Chem Ltd comes first among 3 listed Pharma - Animal companies, followed by Hester Biosciences Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.
How many Animal Health stocks are listed in India?
This comparison covers 3 listed Pharma - Animal companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.
Which Animal Health company is the biggest?
Viyash Scientific Ltd is the largest, with revenue of ₹3,712 crore over the last 12 months, ahead of NGL Fine Chem Ltd at ₹575 crore. That covers 3 of 3 companies with comparable reporting through Sep 2026.
Which Animal Health company has the best profit margins?
Hester Biosciences Ltd has the highest operating margin at 33.7%, from 3 of 3 comparable companies. Hester Biosciences Ltd shows the biggest recent improvement, at +16 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.
Which Animal Health company makes the most profit?
Viyash Scientific Ltd earns the most, at ₹279 crore of net profit over the last 12 months, from 3 of 3 comparable companies.
Hester Biosciences Ltd has the fastest profit growth at the 100% cap of the scoring scale, though growth off a small or recovering profit base overstates how much has actually changed.
Which Animal Health company earns the highest return on capital?
NGL Fine Chem Ltd leads on return on capital employed at 18.6%, across 3 of 3 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.
Is the Animal Health sector beating the market?
Pharma - Animal has done better than the NIFTY 500 by 34.7% over the last 52 weeks, but is 6.3% behind over the last 13 weeks, measured on an equal-weight index of its current members.
Inside the sector, 0 of the 3 companies we track are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Animal Health stock has the strongest price momentum?
NGL Fine Chem Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.
Which Animal Health company has the highest 4-Factor score?
NGL Fine Chem Ltd scores 77.6 out of 100, with 87% of the evidence available, from 35 points on growth and earnings, 18.4 on capital efficiency, 10.2 on valuation and 14 on relative strength.
It ranks published data only; management quality, upcoming events and risks are not part of the score.
How many Animal Health companies does this comparison cover, and over what period?
This comparison covers 3 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.
What is the total market cap of the Animal Health sector?
The 3 Pharma - Animal companies on this page carry ₹13,995 crore of combined market value. Viyash Scientific Ltd is the largest at ₹10,314 crore, about 74% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.
How is the Animal Health sector performing?
0 of the 3 Pharma - Animal companies we track are doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months).
The sector itself is 34.7% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 13 November 2026.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.
Is this advice?
No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.